Using a technique developed at Vanderbilt University Medical Center, researchers identified antibodies that are excellent leads as potential therapies for human parainfluenza virus 3, a leading cause of acute and potentially fatal respiratory illness.

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

Jerome is the 2024 recipient of the Distinguished Scientist Award, which honors “preeminent senior scientists for a long-standing record of achievement in the field of microscopy and microanalysis.”

A new Vanderbilt University Medical Center clinical laboratory facility is open for business following a relocation to a 110,000 square-foot facility in MetroCenter. The new lab is located approximately five miles from VUMC’s main Nashville campus.

A research endeavor that seeks to develop a new cancer immunotherapy utilizing nanobody delivery and targeted heating of tumors has received funding from the Waddell Walker Hancock Cancer Discovery Fund.

Vanderbilt's Romney Humphries, PhD, has received the 2024 John V. Bergen Excellence Award from the Clinical and Laboratory Standards Institute.

The “Molecular Muse” art exhibit on display in Light Hall is a sampling of pieces from the Vanderbilt Institute for Infection, Immunology and Inflammation Artist-in-Residence (VI4-AiR) program, which brings together scientists and artists to create and promote art as a visual science communication tool.